EP3950690A4 - Dérivé pyrrolohétérocyclique, son procédé de préparation et son application en médecine - Google Patents

Dérivé pyrrolohétérocyclique, son procédé de préparation et son application en médecine Download PDF

Info

Publication number
EP3950690A4
EP3950690A4 EP20783525.7A EP20783525A EP3950690A4 EP 3950690 A4 EP3950690 A4 EP 3950690A4 EP 20783525 A EP20783525 A EP 20783525A EP 3950690 A4 EP3950690 A4 EP 3950690A4
Authority
EP
European Patent Office
Prior art keywords
pyrroloheterocyclic
medicine
derivative
preparation
application
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP20783525.7A
Other languages
German (de)
English (en)
Other versions
EP3950690A1 (fr
Inventor
Xin Li
Guodong Cai
Fang Yang
Feng He
Weikang Tao
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shanghai Hengrui Pharmaceutical Co Ltd
Jiangsu Hengrui Pharmaceutical Co Ltd
Original Assignee
Shanghai Hengrui Pharmaceutical Co Ltd
Jiangsu Hengrui Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shanghai Hengrui Pharmaceutical Co Ltd, Jiangsu Hengrui Pharmaceutical Co Ltd filed Critical Shanghai Hengrui Pharmaceutical Co Ltd
Publication of EP3950690A1 publication Critical patent/EP3950690A1/fr
Publication of EP3950690A4 publication Critical patent/EP3950690A4/fr
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
EP20783525.7A 2019-03-29 2020-03-27 Dérivé pyrrolohétérocyclique, son procédé de préparation et son application en médecine Pending EP3950690A4 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201910247297 2019-03-29
CN202010194720 2020-03-19
PCT/CN2020/081591 WO2020200069A1 (fr) 2019-03-29 2020-03-27 Dérivé pyrrolohétérocyclique, son procédé de préparation et son application en médecine

Publications (2)

Publication Number Publication Date
EP3950690A1 EP3950690A1 (fr) 2022-02-09
EP3950690A4 true EP3950690A4 (fr) 2022-12-07

Family

ID=72664469

Family Applications (1)

Application Number Title Priority Date Filing Date
EP20783525.7A Pending EP3950690A4 (fr) 2019-03-29 2020-03-27 Dérivé pyrrolohétérocyclique, son procédé de préparation et son application en médecine

Country Status (11)

Country Link
US (1) US20220185818A1 (fr)
EP (1) EP3950690A4 (fr)
JP (1) JP2022528083A (fr)
KR (1) KR20210146956A (fr)
CN (1) CN113544131B (fr)
AU (1) AU2020251621A1 (fr)
BR (1) BR112021018924A2 (fr)
CA (1) CA3135070A1 (fr)
MX (1) MX2021011823A (fr)
TW (1) TW202102505A (fr)
WO (1) WO2020200069A1 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114829365B (zh) * 2019-12-06 2023-04-25 南京明德新药研发有限公司 作为erk抑制剂的噻唑并内酰胺类化合物及其应用
CN114315837B (zh) * 2020-09-29 2023-06-16 江苏恒瑞医药股份有限公司 一种erk抑制剂的结晶形式及其制备方法
AU2021354821A1 (en) * 2020-09-29 2023-06-08 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Crystal form of pyrrolo heterocyclic derivative and preparation method therefor
WO2022253186A1 (fr) * 2021-06-02 2022-12-08 南京明德新药研发有限公司 Forme cristalline de composé de thiazolopyrrolone à substitution diméthyle et son procédé de préparation
WO2022268065A1 (fr) * 2021-06-22 2022-12-29 Fochon Biosciences, Ltd. Composés en tant qu'inhibiteurs d'erk
TW202341999A (zh) * 2022-03-28 2023-11-01 大陸商江蘇恒瑞醫藥股份有限公司 吡咯并雜環類衍生物的富馬酸鹽的晶型及其製備方法

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999061440A1 (fr) 1998-05-26 1999-12-02 Smithkline Beecham Corporation Nouveaux composes d'imidazole substitue
JP4783532B2 (ja) 2000-02-05 2011-09-28 バーテックス ファーマシューティカルズ インコーポレイテッド Ｅｒｋのインヒビターとして有用なピラゾール組成物
EP1207864A2 (fr) 2000-02-05 2002-05-29 Vertex Pharmaceuticals Incorporated Compositions utiles comme inhibiteurs de erk
IL145756A0 (en) 2000-02-05 2002-07-25 Vertex Pharma Pyrazole derivatives and pharmaceutical compositions containing the same
MXPA03002294A (es) 2000-09-15 2005-09-08 Vertex Pharma Compuestos de pirazol utiles como inhibidores de proteina cinasa.
CN103635472B (zh) 2011-02-28 2018-01-12 阵列生物制药公司 丝氨酸/苏氨酸激酶抑制剂
JP2013010719A (ja) * 2011-06-30 2013-01-17 Dainippon Sumitomo Pharma Co Ltd ベンズイミダゾロンおよびオキシインドール誘導体ならびにそれらの医薬用途
JP5792128B2 (ja) 2011-07-29 2015-10-07 富士フイルム株式会社 １，５−ナフチリジン誘導体又はその塩
US9394297B2 (en) * 2012-02-28 2016-07-19 Amgen Inc. Amides as pim inhibitors
EP2991654B1 (fr) 2013-04-30 2018-11-21 Merck Sharp & Dohme Corp. Nouveaux composés qui sont des inhibiteurs d'erk
MX370906B (es) 2013-12-30 2020-01-09 Genentech Inc Inhibidores de serina/treonina cinasa.
TWI704151B (zh) * 2014-12-22 2020-09-11 美商美國禮來大藥廠 Ｅｒｋ抑制劑
CN107849046B (zh) * 2015-06-03 2020-06-12 常州捷凯医药科技有限公司 作为erk抑制剂的杂环化合物
EP3842429B1 (fr) * 2015-06-15 2022-09-07 Asana BioSciences, LLC Inhibiteurs hétérocycliques de erk1 et erk2 et leur utilisation dans le traitement du cancer
WO2017180817A1 (fr) 2016-04-15 2017-10-19 Musc Foundation For Research Development Traitement de la septicémie et du sdra à l'aide d'inhibiteurs d'erk
JP7201586B6 (ja) 2016-09-08 2024-02-08 サビラ バイオサイエンシズ エルエルシー 神経保護作用、自己免疫性ならびに癌の疾患および病状において有用な１，２－ジチオラン化合物

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
No further relevant documents disclosed *

Also Published As

Publication number Publication date
KR20210146956A (ko) 2021-12-06
CN113544131B (zh) 2024-03-15
AU2020251621A1 (en) 2021-11-04
US20220185818A1 (en) 2022-06-16
WO2020200069A1 (fr) 2020-10-08
CN113544131A (zh) 2021-10-22
CA3135070A1 (fr) 2020-10-08
JP2022528083A (ja) 2022-06-08
EP3950690A1 (fr) 2022-02-09
MX2021011823A (es) 2021-10-22
BR112021018924A2 (pt) 2022-02-01
TW202102505A (zh) 2021-01-16

Similar Documents

Publication Publication Date Title
EP3858840A4 (fr) Dérivé macrocyclique d'indole, son procédé de préparation et son application en médecine
EP3733659A4 (fr) Dérivé de vinyle aromatique ou d'éthyle aromatique, procédé de préparation associé, intermédiaire, composition pharmaceutique et application
EP3750887A4 (fr) Dérivé de biaryle, son procédé de préparation, et son application pharmaceutique
EP3907218A4 (fr) Dérivé de 6-oxo-1,6-dihydropyridazine, son procédé de préparation et son utilisation médicale
EP3569596A4 (fr) Dérivé de 1,2,4-triazine-3-amine, son procédé de préparation et son utilisation en médecine
EP3950690A4 (fr) Dérivé pyrrolohétérocyclique, son procédé de préparation et son application en médecine
EP3636646A4 (fr) Dérivés d'hétéroaryle pyrazole, leur procédé de préparation et leur application médicale
EP3486242A4 (fr) Dérivé d'oxopicolinamide, son procédé de préparation et son utilisation pharmaceutique
EP3862348A4 (fr) Composé d'isoindoline, procédé de préparation, composition pharmaceutique et utilisation associée
EP3967687A4 (fr) Dérivé de phénylpropénylpyridine substitué, son procédé de préparation et son utilisation médicale
EP4063363A4 (fr) Dérivé pyrazolo-hétéroaryl, son procédé de préparation et son utilisation médicale
EP3822271A4 (fr) Dérivé de pyridopyrimidine, son procédé de préparation et son utilisation médicale
EP3650448A4 (fr) Dérivé d'indole-formamide, son procédé de préparation et son utilisation en médecine
EP3744316A4 (fr) Composition pharmaceutique ophtalmique, son procédé de préparation et son application
EP3858833A4 (fr) Dérivé d'aminonordécane, son procédé de préparation et son utilisation
EP4059930A4 (fr) Dérivé d'amide et son procédé de préparation et son application en médecine
EP3632906A4 (fr) Dérivé d'azaaryle, son procédé de préparation et son application pour une utilisation en pharmacie
EP3929181A4 (fr) Dérivé de promédicament de 6-oxo -1,6-dihydropyridazine, son procédé de préparation et son application en médecine
EP4082534A4 (fr) Préparation solide, son procédé de préparation et son utilisation
EP4056571A4 (fr) Dérivé de dihydroimidazopyrimidone tricyclique, son procédé de préparation, composition pharmaceutique et son utilisation
EP3808751A4 (fr) Dérivé de camptothécine, procédé de préparation correspondant et utilisation associée
EP4079734A4 (fr) Dérivé de triazolopyridazine, son procédé de préparation, composition pharmaceutique associée et utilisation correspondante
EP3760191A4 (fr) Composition pharmaceutique, procédé de préparation et utilisation de cette dernière
EP4053154A4 (fr) Kératine bd-10, son procédé de préparation, et composition pharmaceutique de celle-ci, et son utilisation
EP4053152A4 (fr) Kératine bd-13, procédé de préparation, composition pharmaceutique et utilisation de celle-ci

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20210923

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
RAP3 Party data changed (applicant data changed or rights of an application transferred)

Owner name: SHANGHAI HENGRUI PHARMACEUTICAL CO., LTD.

Owner name: JIANGSU HENGRUI PHARMACEUTICALS CO., LTD.

A4 Supplementary search report drawn up and despatched

Effective date: 20221108

RIC1 Information provided on ipc code assigned before grant

Ipc: A61P 29/00 20060101ALI20221102BHEP

Ipc: A61P 35/00 20060101ALI20221102BHEP

Ipc: A61K 31/519 20060101ALI20221102BHEP

Ipc: A61K 31/4188 20060101ALI20221102BHEP

Ipc: C07D 487/04 20060101AFI20221102BHEP